Attitudes Towards Clinical Trials Among Patients with Sickle Cell Disease
Links to Fileshttps://journals.sagepub.com/doi/10.1177/1740774513519876
MetadataShow full item record
Type of Work16 pages
journal articles postprints
Citation of Original PublicationHaywood, Carlton, Sophie Lanzkron, Marie Diener-West, Jennifer Haythornthwaite, John J Strouse, Shawn Bediako, Gladys Onojobi, and Mary Catherine Beach. “Attitudes toward Clinical Trials among Patients with Sickle Cell Disease.” Clinical Trials 11, no. 3 (June 2014): 275–83. doi:10.1177/1740774513519876.
RightsThis item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
This is not the final published version. Carlton Haywood, Jr, Sophie Lanzkron, Marie Diener-West, Jennifer Haythornthwaite, John J Strouse, Shawn Bediako, Gladys Onojobi, Mary Catherine Beach, for the IMPORT Investigators, Attitudes toward clinical trials among patients with sickle cell disease,Clinical Trials (Volume Number 11 and Issue Number 3) pp. 275–283. Copyright ©2020 SAGE Publications. DOI: 10.1177/1740774513519876.
Background A substantial number of planned clinical trials for sickle cell disease (SCD) have terminated early due to insufficient patient enrollment. Purpose To describe attitudes toward clinical trials among a sample of adults with SCD and identify patient-level factors associated with these attitudes. Methods Our data came from a sample (N = 291) of primarily adults with SCD participating in the Improving Patient Outcomes with Respect and Trust (IMPORT) study, which is a federally funded observational study of SCD patient experiences in seeking healthcare. Attitudes toward clinical trials were assessed using items from the Perceptions of Participation in Clinical Research instrument. Patient factors examined as potential correlates of clinical trial attitudes were demographics, disease severity, engagement in self-care, trust, healthcare experience ratings, and prior history of participation in clinical trials. Multiple regression analyses were used to identify patient-level correlates of clinical trial attitudes. Results Our sample of SCD patients expressed overwhelmingly favorable attitudes about clinical trials, with 77%–92% of our sample expressing agreement with a series of positive statements about clinical trials in general. Demographics, engagement in self-care, healthcare experience ratings, and prior trial participation each explained significant portions of the variability in clinical trial attitudes. Limitations The generalizability of our results to the entire SCD population may be of concern as the study participants were all receiving care at comprehensive sickle cell centers and already participating in clinical research. Conclusion Our results suggest that, in principle, adults with SCD enrolled in an observational study express very positive general attitudes about clinical trial participation and that specific factors attached to particular clinical trial opportunities may play a greater role in a SCD patient’s decision to participate than a general unwillingness to participate.